The fast, safe solution for vascular thrombosis.

**The EkoSonic™ Endovascular System:**
- **Quality clinical outcomes**
- **Predictable results**
- **Minimized bleeding risk**
- **Efficient procedures**

**Deep Vein Thrombosis:**
- 50% of DVT patients have PC
- Faster, more complete thrombosis compared to CDT
- Reduces post-thrombotic syndrome

**Arterial Occlusion:**
- Lower 10-day amputation rate
- Lower bleeding rates when compared to CDT
- Higher complete dissolution rate compared to CDT

**Pulmonary Embolism:**
- 50% of DVT patients have PE
- 50% less thrombolytic drug dosage than standard treatment
- Maintained risk of bleeding

**References**


**Distribution:**

The EkoSonic™ Endovascular System is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. The EkoSonic™ Endovascular System is CE Marked for the treatment of pulmonary embolism with a ≥50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries. Treatment is not designed for peripheral vasculature dilation purposes. This system is contraindicated in patients with an allergy to aspirin or clopidogrel. For complete information on this system, please visit www.ekoscorp.com.

**About EKOS™**

EKOS Corporation is a BTG International group company, committed to developing and delivering innovative ultrasound and catheter delivery technologies for the treatment of vascular conditions and for improved patient outcomes. EKOS’ proprietary EkoSonic™ technology is the fast, safe solution for vascular thrombosis.

**About BTG**

BTG is a growing international specialist healthcare company, ranging in market access from cardiovascular interventions to specialized areas of treatment to either venous or arterial disease, and their patients. We have a portfolio of innovative, advanced medical, advanced medical, non-invasive therapies, and a broad range of medical devices. BTG is committed to continual innovation in these areas, required by patient and physician needs. We are seeking to support the patient in addition of family and co-morbid conditions.

**Contact us:**

EKOS, 400 Hicks Lane, Menlo Park, CA 94025 USA
Phone: +1 650-551-2400
Website: www.ekoscorp.com
Email: customerservice@ekoscorp.com

**Online Learning Center:**

www.ekoscorp.com/learningcenter

**Medical Device Information:**

The EkoSonic™ Endovascular System is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. The EkoSonic™ Endovascular System is CE Marked for the treatment of pulmonary embolism with a ≥50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries. Treatment is not designed for peripheral vasculature dilation purposes. This system is contraindicated in patients with an allergy to aspirin or clopidogrel. For complete information on this system, please visit www.ekoscorp.com.

**INDICATIONS FOR USE:**

The EkoSonic™ Endovascular System is intended for controlled and selective infusion of physician-specified fluids, including thrombolytics, into the peripheral vasculature. The EkoSonic™ Endovascular System is CE Marked for the treatment of pulmonary embolism with a ≥50% clot burden in one or both main pulmonary arteries or lobar pulmonary arteries. Treatment is not designed for peripheral vasculature dilation purposes. This system is contraindicated in patients with an allergy to aspirin or clopidogrel. For complete information on this system, please visit www.ekoscorp.com.

**The Fast, Safe Solution for Vascular Thrombosis.**

**The EkoSonic™ Endovascular System:**
- **Quality clinical outcomes**
- **Predictable results**
- **Minimized bleeding risk**
- **Efficient procedures**

**Deep Vein Thrombosis:**
- 50% of DVT patients have PC
- Faster, more complete thrombosis compared to CDT
- Reduces post-thrombotic syndrome

**Arterial Occlusion:**
- Lower 10-day amputation rate
- Lower bleeding rates when compared to CDT
- Higher complete dissolution rate compared to CDT

**Pulmonary Embolism:**
- 50% of DVT patients have PE
- 50% less thrombolytic drug dosage than standard treatment
- Maintained risk of bleeding

**References**


The fast, safe solution for vascular thrombosis.

The EkoSonic™ Endovascular System:
- Quality clinical outcomes
- Predictable results
- Minimised bleeding risk
- Efficient procedures

Quickly & safely dissolve thrombus with the EKOS™ System. Treat smarter. Achieve more.

Since its beginning, EKOS™ has had one goal: develop life-enhancing and lifesaving endovascular treatments. EKOS™ is committed to developing device-based therapies that improve patient outcomes, lower risk and improve treatment predictability.

The EkoSonic™ Endovascular System includes an ultrasonic core within an infuser catheter, and control unit.

EKOS® Acoustic Pulse Thrombolysis™ treatment most of the drug remains in the thrombus and you can typically use less lytic. To dissolve the thrombus without damaging vessels, veins or walls,13 there is no mechanical disruption resulting in distal embolisation.13

The EKOS® System’s safety and efficacy is supported by Level 1 and Level 2 data.6, 7, 14, 15

EKOS™ requires significantly shorter treatment times, typically only 30–50% of standard CDT. Unlike more complex surgical solutions,1, 5 EKOS™ is an efficient, three-step process:
1) Insert the EKOS™ 5.4F infusion catheter through the thrombus.
2) Insert the ultrasonic core until it locks in place.
3) Activate the lytic infusion and acoustic pulse.

Treatment zones range from 6cm to 50cm with radiopaque marker bands at each end of the treatment zone to enhance visualisation. At-a-glance operating status, alarms and treatment times are easy to read from a distance.